Account
Articles
16.06.2025
HST or STA? Navigating NICE’s Dual Pathways for ...

When bringing a new health technology to market in England, pharmaceutical and biotech companies mus...

Read more
Articles
02.06.2025
Joint Scientific Consultations: When, Why, and How...

The increasing complexity of bringing innovative therapies to market across various jurisdictions pr...

Read more
Articles
19.05.2025
Avoiding Common Pitfalls in HTA Scientific Advice:...

With the implementation of the EU HTA (Regulation (EU) 2025/117) and ongoing adaptation of methods u...

Read more
Articles
12.05.2025
Driving Internal Alignment: How Early HTA Advice U...

As the regulatory and market access landscape continues to evolve across Europe, timely and strategi...

Read more
Articles
07.05.2025
Unlocking Payer Confidence: Why Early HTA Scientif...

In the current pharmaceutical environment, obtaining regulatory approval is no longer enough to ensu...

Read more
Insider Insights
28.04.2025
HTA Spotlight: First EU Joint Clinical Assessments...

The first joint clinical assessments under the new EU Health Technology Assessment (HTA) Regulation ...

Read more
Articles
23.04.2025
EU HTA Regulation for Medical Devices Starts in 20

The long-anticipated EU Health Technology Assessment (HTA) Regulation (Regulation (EU) 2021/2282) wa...

Read more
Insider Insights
14.04.2025
Reflections on the March 2025 EU HTA Webinar 

On 21 March 2025, the European Commission hosted a public webinar to share updates on the implementa...

Read more
Insider Insights
09.04.2025
25 Years of NICE: Reflections and Achievements

Celebrating its 25th anniversary, NICE hosted a conference looking back at its progress and ahead to...

Read more
Articles
07.04.2025
Reforming Health Technology Assessments to Embrace...

The advent of cell and gene therapies (CGTs) represents a paradigm shift in medicine, offering the p...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.